ArticlePathology oncology research : POR2011
Female breast cancer status according to ER, PR and HER2 expression: a population based analysis.
Article in Pathology oncology research : POR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Genetic and lifestyle factors for breast cancer risk assessment in Southeast China.Cancer medicine · 2023Trial
- Relative and disease-free survival for breast cancer in relation to subtype: a population-based study.Journal of cancer research and clinical oncology · 2013Trial
- Multi-Level Profiling of MAPK-Associated Genes and MicroRNAs Uncovers Regulatory Networks in Breast Cancer Subtypes.International journal of molecular sciences · 2025Article
- Association Between Microcalcification Patterns in Mammography and Breast Tumors in Comparison to Histopathological Examinations.Diagnostics (Basel, Switzerland) · 2025Article
- Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland.Breast cancer research : BCR · 2025Article
- Ultrasound-based radiomics for the evaluation of breast cancer.Frontiers in oncology · 2025Review
- Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer.Current issues in molecular biology · 2024Article
- Machine learning-based model constructed from ultrasound radiomics and clinical features for predicting HER2 status in breast cancer patients with indeterminate (2+) immunohistochemical results.Cancer medicine · 2024Article
- Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor.International journal of molecular sciences · 2023Article
- Risk factors and survival of triple-negative breast cancer among breast cancer patients: Ten-year cross-sectional study in the southwestern Iranian population.Health science reports · 2023Article
- Female breast cancer subtypes in the Romagna Unit of the Emilia-Romagna cancer registry, and estimated incident cases by subtypes and age in Italy in 2020.Journal of cancer research and clinical oncology · 2023Article
- 10-year survival in female breast cancer patients according to ER, PR and HER2 expression: a cancer registry population-based analysis.Journal of cancer research and clinical oncology · 2023Article
- Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.NPJ breast cancer · 2023Review
- Immunohistochemical HER2 Recognition and Analysis of Breast Cancer Based on Deep Learning.Diagnostics (Basel, Switzerland) · 2023Article
- Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia.Frontiers in endocrinology · 2023Article
- The impact of age group in breast cancer survival outcome according to neoadjuvant treatment response: A matched case-control study.The Kaohsiung journal of medical sciences · 2022Article
- Molecular Subtypes, Metastatic Pattern and Patient Age in Breast Cancer: An Analysis of Italian Network of Cancer Registries (AIRTUM) Data.Journal of clinical medicine · 2021Article
- Clinico-radio-pathological Features and Biological Behavior of Breast Cancer in Young Indian Women: A Prospective Study.The Indian journal of radiology & imaging · 2021Article
- Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database.JCO global oncology · 2020Article
- Expression pattern of p-Smad2/Smad4 as a predictor of survival in invasive breast ductal carcinoma.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to evaluate the prognostic values of some biological parameters in a population based series of female breast cancer patients. Through the Tuscan Cancer Registry all the invasive breast cancer cases diagnosed during the period 2004-2005 in the provinces of Florence and Prato, central Italy, were retrieved. Molecular subtypes were analyzed defined by immunohistochemical markers, by age, tumor size, lymph node status, histotype, grade of differentiation and proliferative marker. Out of 1487 patients 70.3% were luminal A subtype (ER/PR + HER2-), 15.6% luminal B (ER/PR + HER2+), 8.1% triple negative (ER/PR-HER2-), 6.0% HER2+ (ER/PR-HER2+); the 3 year survival rates were 93.3%, 89.5%, 86.3%, 82.7% respectively (p < 0.001). Analysis of survival by the Cox proportional hazards model showed an independent prognostic value of molecular classification. Our study revealed significant differences in clinicopathological characteristics among breast cancer molecular subtypes and confirmed their prognostic independent role.
Indexed as
Identifiers
21479875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.